These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 24773585)
1. Mechanisms of cellular uptake, intracellular transportation, and degradation of CIGB-300, a Tat-conjugated peptide, in tumor cell lines. Benavent Acero FR; Perera Negrin Y; Alonso DF; Perea SE; Gomez DE; Farina HG Mol Pharm; 2014 Jun; 11(6):1798-807. PubMed ID: 24773585 [TBL] [Abstract][Full Text] [Related]
2. Sensitivity of tumor cells towards CIGB-300 anticancer peptide relies on its nucleolar localization. Perera Y; Costales HC; Diaz Y; Reyes O; Farina HG; Mendez L; Gómez RE; Acevedo BE; Gomez DE; Alonso DF; Perea SE J Pept Sci; 2012 Apr; 18(4):215-23. PubMed ID: 22407768 [TBL] [Abstract][Full Text] [Related]
3. Cellular internalization mechanism and intracellular trafficking of filamentous M13 phages displaying a cell-penetrating transbody and TAT peptide. Kim A; Shin TH; Shin SM; Pham CD; Choi DK; Kwon MH; Kim YS PLoS One; 2012; 7(12):e51813. PubMed ID: 23251631 [TBL] [Abstract][Full Text] [Related]
4. CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo. Perea SE; Reyes O; Baladron I; Perera Y; Farina H; Gil J; Rodriguez A; Bacardi D; Marcelo JL; Cosme K; Cruz M; Valenzuela C; López-Saura PA; Puchades Y; Serrano JM; Mendoza O; Castellanos L; Sanchez A; Betancourt L; Besada V; Silva R; López E; Falcón V; Hernández I; Solares M; Santana A; Díaz A; Ramos T; López C; Ariosa J; González LJ; Garay H; Gómez D; Gómez R; Alonso DF; Sigman H; Herrera L; Acevedo B Mol Cell Biochem; 2008 Sep; 316(1-2):163-7. PubMed ID: 18575815 [TBL] [Abstract][Full Text] [Related]
5. Cell Penetrating Capacity and Internalization Mechanisms Used by the Synthetic Peptide CIGB-552 and Its Relationship with Tumor Cell Line Sensitivity. Astrada S; Fernández Massó JR; Vallespí MG; Bollati-Fogolín M Molecules; 2018 Mar; 23(4):. PubMed ID: 29601540 [TBL] [Abstract][Full Text] [Related]
6. Anticancer peptide CIGB-300 binds to nucleophosmin/B23, impairs its CK2-mediated phosphorylation, and leads to apoptosis through its nucleolar disassembly activity. Perera Y; Farina HG; Gil J; Rodriguez A; Benavent F; Castellanos L; Gómez RE; Acevedo BE; Alonso DF; Perea SE Mol Cancer Ther; 2009 May; 8(5):1189-96. PubMed ID: 19417160 [TBL] [Abstract][Full Text] [Related]
7. Characterization of low-abundance species in the active pharmaceutical ingredient of CIGB-300: A clinical-grade anticancer synthetic peptide. Garay H; Espinosa LA; Perera Y; Sánchez A; Diago D; Perea SE; Besada V; Reyes O; González LJ J Pept Sci; 2018 Jun; 24(6):e3081. PubMed ID: 29676523 [TBL] [Abstract][Full Text] [Related]
8. CIGB-300, an anti-CK2 peptide, inhibits angiogenesis, tumor cell invasion and metastasis in lung cancer models. Benavent Acero F; Capobianco CS; Garona J; Cirigliano SM; Perera Y; Urtreger AJ; Perea SE; Alonso DF; Farina HG Lung Cancer; 2017 May; 107():14-21. PubMed ID: 27319334 [TBL] [Abstract][Full Text] [Related]
14. Endocytosis and Trafficking of Heparan Sulfate Proteoglycans in Triple-Negative Breast Cancer Cells Unraveled with a Polycationic Peptide. Mandarini E; Tollapi E; Zanchi M; Depau L; Pini A; Brunetti J; Bracci L; Falciani C Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167372 [TBL] [Abstract][Full Text] [Related]
15. CIGB-300, a synthetic peptide-based drug that targets the CK2 phosphoaceptor domain. Translational and clinical research. Perea SE; Baladron I; Garcia Y; Perera Y; Lopez A; Soriano JL; Batista N; Palau A; Hernández I; Farina H; Garcia I; Gonzalez L; Gil J; Rodriguez A; Solares M; Santana A; Cruz M; Lopez M; Valenzuela C; Reyes O; López-Saura PA; González CA; Diaz A; Castellanos L; Sanchez A; Betancourt L; Besada V; González LJ; Garay H; Gómez R; Gómez DE; Alonso DF; Perrin P; Renualt JY; Sigman H; Herrera L; Acevedo B Mol Cell Biochem; 2011 Oct; 356(1-2):45-50. PubMed ID: 21735096 [TBL] [Abstract][Full Text] [Related]
16. Tat(48-60) peptide amino acid sequence is not unique in its cell penetrating properties and cell-surface glycosaminoglycans inhibit its cellular uptake. Subrizi A; Tuominen E; Bunker A; Róg T; Antopolsky M; Urtti A J Control Release; 2012 Mar; 158(2):277-85. PubMed ID: 22100438 [TBL] [Abstract][Full Text] [Related]
17. The synthetic peptide CIGB-300 modulates CK2-dependent signaling pathways affecting the survival and chemoresistance of non-small cell lung cancer cell lines. Cirigliano SM; Díaz Bessone MI; Berardi DE; Flumian C; Bal de Kier Joffé ED; Perea SE; Farina HG; Todaro LB; Urtreger AJ Cancer Cell Int; 2017; 17():42. PubMed ID: 28373828 [TBL] [Abstract][Full Text] [Related]